Biocartis (BCART)

Executive Summary

Biocartis is a Belgian molecular diagnostics company revolutionizing oncology testing with its proprietary Idylla™ platform, a fully automated, sample-to-result system that delivers rapid, accurate results from a variety of sample types. The platform addresses key limitations of traditional molecular testing by eliminating complex workflows and reducing turnaround times to under two hours, enabling broader access to precision medicine. Biocartis has built a comprehensive menu of assays, including liquid biopsy options, and has secured commercial partnerships with leading pharmaceutical companies. Despite near-term headwinds from the transition to new EU IVDR regulations, the company's strong IP portfolio, installed base growth, and recurring revenue from consumables position it for sustained growth. Recent financial results show improving gross margins and a path to profitability, supported by disciplined cost management and expanding reimbursement coverage in key markets like the US and EU.

Upcoming Catalysts (preview)

• Q3 2026CE-IVDR certification for expanded Idylla menu85% success
• TBDAnnouncement of new pharma partnership for companion diagnostic development60% success
• Q3 2026Q2 2026 earnings report with accelerated revenue growth and margin improvement70% success